The U.S. Food and Drug Administration has suspended the license for Valneva's chikungunya vaccine, Ixchiq, following reports of serious adverse events consistent with chikungunya-like illness in recipients, including one death directly attributable to the vaccine. Despite prior accelerated approval, the agency determined that the vaccine's safety profile no longer supports its intended use, requiring an immediate halt to shipments and sales in the U.S. This regulatory action reflects heightened scrutiny over adverse events post-approval.